Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer.

  • Lee W
  • Ladouceur G
  • Dumas J
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.

Abstract

Title compds. I [R1-2 = H, alkyl, halo; A = Ph, pyridine, pyrimidine; B = phenylene, naphthylene; L = O, S, CH2; M = Ph, pyridine, pyrimidine; n = 0-1; X = O, SO2, etc.; Y = alkoxy, oxycarbonyl, amino, etc.] are prepd. For instance, II is prepd. from 4-[3-tert-butyl-5-[N'-[4-(pyridin-4-yloxy)phenyl]ureido]pyrazol-1-yl]benzoic acid Me ester (prepn. given) and 2-(pyrrolidin-1-yl)ethylamine (DCE, AlMe3, 80°, 16 h). Compds. of the invention show significant inhibition of TrkA kinase (IC50 < 1 μM). I are useful for the treatment of cancer. [on SciFinder(R)]

Cite

CITATION STYLE

APA

Lee, W., Ladouceur, G., Dumas, J., Smith, R., Ying, S., Wang, G., … Mokdad, H. Hatoum. (2005, November 24). Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer. PCT Int. Appl. Bayer Pharmaceuticals Corporation, USA .

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free